Wide Ranks

ALVO

Alvotech

11.68

Top Statistics
Market Cap 3 B Forward PE 45.18 Revenue Growth 4399.70 %
Current Ratio 0.24 Trailing PE 0.0000 Earnings Growth -69.60 %
Profit Margins -200.30 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -43.52 Enterprise / Revenue 14.74 Price To Sales Trailing12 Months 11.42
Profitability
Profit Margins -200.30 % Operating Margins 46.22 %
Balance Sheet
Total Cash 10 M Total Cash Per Share 0.0390 Total Debt 1 B
Total Debt To Equity Current Ratio 0.24 Book Value Per Share -3.50
All Measures
Short Ratio 58.00 % Message Board Id finmb_693209405 Shares Short Prior Month 80195
City Luxembourg City Uuid abc02b5d-5044-3532-9d0d-b9db1659ed78 Previous Close 11.84
First Trade Date Epoch Utc 1 B Book Value -3.50 Beta -0.0970
Total Debt 1 B Volume 62728 Fifty Two Week Low 9.08
Total Cash Per Share 0.0390 Total Revenue 308 M Shares Short Previous Month Date 1 B
Target Median Price 18.00 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Operating Margins 46.22 % Target Mean Price 17.40
Net Income To Common -618380992 Short Percent Of Float 0.0007 Implied Shares Outstanding 301 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 52220
Average Volume10days 52220 Total Cash 10 M Next Fiscal Year End 1 B
Revenue Per Share 1.28 Held Percent Insiders 0.6401 Ebitda Margins -33.87 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 11.84 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 12.30 Open 11.88 Free Cashflow -287744736
Dividend Yield 0.00 % Return On Assets -0.0761 Time Zone Short Name EST
Trailing Eps -1.85 Day Low 11.62 Address1 9, Rue de Bitbourg
Shares Outstanding 301 M Price Hint 2 Target High Price 28.00
Website https://www.alvotech.com 52 Week Change 0.2295 Average Volume 94753
Earnings Quarterly Growth -65.50 % Forward Eps 0.2000 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 13.20 % Is_sp_500 False
Regular Market Day High 11.88 Profit Margins -200.30 % Fifty Two Week High 18.00
Day High 11.88 Shares Short 79013 Regular Market Open 11.88
Industry Key drug-manufacturers-specialty-generic Earnings Growth -69.60 % Enterprise To Revenue 14.74
Revenue Growth 4399.70 % Shares Percent Shares Out 0.0003 Operating Cashflow -310183008
Currency USD Time Zone Full Name America/New_York Market Cap 3 B
Is_nasdaq_100 False Zip 1273 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Alvotech Regular Market Day Low 11.62
Held Percent Institutions 0.0604 Current Price 11.68 Enterprise To Ebitda -43.52
Financial Currency USD Current Ratio 0.24 Gross Margins 48.79 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 5 Country Luxembourg
Float Shares 98 M Two Hundred Day Average 12.91 Enterprise Value 4 B
Price To Sales Trailing12 Months 11.42 Forward PE 45.18 Regular Market Volume 62728
Ebitda -104551000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product.

Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.